Aisling Capital III LP insider trades: Loxo Oncology (LOXO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Aisling Capital III LP reports to the SEC
and 4 more companies
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 10, 2018 | LOXO | ↓ Sell | 1,400,000 | $179.43 | $251.2M | Direct | Jul 12, 2018 (2d) |
| Dec 19, 2017 | LOXO | ↓ Sell | 250,000 | $80.50 | $20.1M | Direct | Dec 20, 2017 (1d) |
| Nov 22, 2017 | LOXO | ↓ Sell | 500,000 | $75.00 | $37.5M | Direct | Nov 27, 2017 (5d) |
| Jan 10, 2017 | LOXO | ↑ Buy | 160,000 | $31.00 | $5.0M | Direct | Jan 12, 2017 (2d) |
| Jul 6, 2016 | SYRS | ↑ Buy | 400,000 | $12.50 | $5.0M | Direct | Jul 6, 2016 (0d) |
| May 17, 2016 | LOXO | ↑ Buy | 232,558 | $21.50 | $5.0M | Direct | May 19, 2016 (2d) |
| Dec 11, 2015 | LOXO | ↑ Buy | 200 | $27.50 | $6K | Direct | Dec 15, 2015 (4d) |
| Dec 9, 2015 | TTOO | ↑ Buy | 307,692 | $9.75 | $3.0M | Indirect | Dec 9, 2015 (0d) |
| Nov 17, 2015 | LOXO | ↑ Buy | 265,000 | $26.50 | $7.0M | Direct | Nov 19, 2015 (2d) |
| Nov 13, 2015 | LOXO | ↑ Buy | 78,669 | $27.65 | $2.2M | Direct | Nov 16, 2015 (3d) |
| Jan 27, 2015 | VSAR | ↑ Buy | 145,000 | $17.25 | $2.5M | See FN | Jan 29, 2015 (2d) |
| Jan 23, 2015 | AGRX | ↑ Buy | 811,966 | $5.85 | $4.8M | See FN | Jan 27, 2015 (4d) |
| Aug 12, 2014 | TTOO | ↑ Buy | 454,545 | $11.00 | $5.0M | Indirect | Aug 14, 2014 (2d) |
| Aug 6, 2014 | LOXO | ↑ Buy | 413,077 | $13.00 | $5.4M | Direct | Aug 6, 2014 (0d) |
| Apr 21, 2014 | TRXC | ↑ Buy | 1,037,767 | $4.00 | $4.2M | By Aisling Capital III, LP | Apr 23, 2014 (2d) |
| Mar 26, 2014 | VSAR | ↑ Buy | 60,000 | $21.00 | $1.3M | See FN | Mar 27, 2014 (1d) |
| Mar 21, 2014 | DRTX | ↓ Sell | 100,649 | $15.74 | $1.6M | By Aisling Capital III, LP | Mar 21, 2014 (0d) |
| Nov 14, 2013 | ZLTQ | ↓ Sell | 575,000 | $12.22 | $7.0M | By Aisling Capital III, LP | Nov 15, 2013 (1d) |
| Jul 24, 2012 | DRTX | ↑ Buy | 1,111,111 | $9.00 | $10.0M | By Aisling Capital III, LP | Jul 25, 2012 (1d) |
| Oct 24, 2011 | ZLTQ | ↑ Buy | 769,231 | $13.00 | $10.0M | Indirect | Oct 25, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Aisling Capital III LP's insider trades
Aisling Capital III LP is a 10% owner of Loxo Oncology (LOXO). Since Oct 24, 2011, it has reported 15 open-market purchases worth $70.2M and 5 sales worth $317.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (6 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LOXO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.